Literature DB >> 10589949

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.

C V Paya1, J J Fung, M A Nalesnik, E Kieff, M Green, G Gores, T M Habermann, P H Wiesner, J L Swinnen, E S Woodle, J S Bromberg.   

Abstract

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

Entities:  

Mesh:

Year:  1999        PMID: 10589949     DOI: 10.1097/00007890-199911270-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  79 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

3.  Small intestinal lymphoma in a post-renal transplant patient: a rare case with late presentation.

Authors:  Ritesh Kumar; Divya Khosla; Rakesh Kapoor; Shreekant Bharti
Journal:  J Gastrointest Cancer       Date:  2014-12

4.  Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.

Authors:  Chikashi Nakanishi; Naoki Kawagishi; Satoshi Sekiguchi; Yorihiro Akamatsu; Kazushige Sato; Shigehito Miyagi; Ikuo Takeda; Daizo Fukushima; Yoshinobu Kobayashi; Kazuyuki Ishida; Hidetaka Niizuma; Shigeru Tsuchiya; Motoshi Wada; Masaki Nio; Susumu Satomi
Journal:  Surg Today       Date:  2012-01-26       Impact factor: 2.549

5.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 6.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 7.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 8.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

9.  EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Authors:  Deirdre O'Mahony; John C Morris; Maryalice Stetler-Stevenson; Helen Matthews; Margaret R Brown; Thomas Fleisher; Stefania Pittaluga; Mark Raffeld; Paul S Albert; Dirk Reitsma; Karen Kaucic; Luz Hammershaimb; Thomas A Waldmann; John E Janik
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

10.  EBNA3C interacts with Gadd34 and counteracts the unfolded protein response.

Authors:  Jose L Garrido; Seijii Maruo; Kenzo Takada; Adam Rosendorff
Journal:  Virol J       Date:  2009-12-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.